Text Module


Share

Program Content

Activities

  • BTKi Resistance in CLL
    A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 01, 2024

    Expires: March 31, 2025

Faculty

cover img faculity

Matthew S Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Leader, Lymphoma Program
Dana-Farber/Harvard Cancer Center
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

cover img faculity

Lindsey Roeker, MD

Assistant Attending
CLL Program Director
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from AstraZeneca

AstraZeneca